Trial Profile
A phase I dose escalation study with everolimus in combination with cyclosporine A [cyclosporin] and prednisolone for the treatment of acute GVHD [graft-versus-host disease] after allogeneic hematopoietic stem cell transplantation.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Prednisolone
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 18 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Oct 2006 New trial record.